Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to 29.29%.

  • Ascendis Pharma A's EBITDA Margin rose 1419700.0% to 29.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 47230.0%, marking a year-over-year increase of 473067100.0%. This contributed to the annual value of 68.7% for FY2024, which is 817900.0% up from last year.
  • As of Q3 2025, Ascendis Pharma A's EBITDA Margin stood at 29.29%, which was up 1419700.0% from 25.47% recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's EBITDA Margin peaked at 123555.16% during Q4 2024, and registered a low of 13140.61% during Q2 2021.
  • In the last 5 years, Ascendis Pharma A's EBITDA Margin had a median value of 303.81% in 2024 and averaged 4650.46%.
  • Per our database at Business Quant, Ascendis Pharma A's EBITDA Margin plummeted by -65195100bps in 2021 and then soared by 1235672600bps in 2024.
  • Ascendis Pharma A's EBITDA Margin (Quarter) stood at 130.71% in 2021, then plummeted by -393bps to 643.75% in 2022, then skyrocketed by 98bps to 12.09% in 2023, then surged by 1021723bps to 123555.16% in 2024, then crashed by -100bps to 29.29% in 2025.
  • Its EBITDA Margin stands at 29.29% for Q3 2025, versus 25.47% for Q2 2025 and 93.81% for Q1 2025.